Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.
A patient with a pituitary adenoma secreting follicle-stimulating hormone with co-existent primary hyperaldosteronism is described. After his second transsphenoidal surgery, the patient developed a Staphylococcus aureus pituitary abscess. Symptoms improved after abscess drainage. Subsequent cabergoline therapy arrested the deterioration of symptoms. and decreased serum follicle-stimulating hormone concentrations. Cabergoline may be a useful treatment for aggressively growing non-prolactin-secreting pituitary adenomas.
Leese
G
G
Department of Medicine, Royal liverpool University Hospital, UK.
Jeffreys
R
R
Vora
J
J
D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005640:Follicle Stimulating Hormone / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D000970:Antineoplastic Agents; D018491:Dopamine Agonists; D004873:Ergolines; D005640:Follicle Stimulating Hormone; D000077465:Cabergoline